Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2008;117:1945-1954
Published online before print March 31, 2008, doi: 10.1161/CIRCULATIONAHA.107.720847
Free Article
This Article
Free upon publication Free Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
117/15/1945    most recent
CIRCULATIONAHA.107.720847v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow patientINFORMation
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schramm, T. K.
Right arrow Articles by Torp-Pedersen, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schramm, T. K.
Right arrow Articles by Torp-Pedersen, C.
Related Collections
Right arrow Type 1 diabetes
Right arrow Type 2 diabetes
Right arrow Epidemiology
Right arrowRelated Article

(Circulation. 2008;117:1945-1954.)
© 2008 American Heart Association, Inc.


Epidemiology

Diabetes Patients Requiring Glucose-Lowering Therapy and Nondiabetics With a Prior Myocardial Infarction Carry the Same Cardiovascular Risk

A Population Study of 3.3 Million People

Tina Ken Schramm, MD; Gunnar H. Gislason, MD; Lars Køber, MD, DMSc; Søren Rasmussen, MSc, PhD; Jeppe N. Rasmussen, MD, PhD; Steen Z. Abildstrøm, MD, PhD; Morten Lock Hansen, MD; Fredrik Folke, MD; Pernille Buch, MD; Mette Madsen, MSc; Allan Vaag, MD, DMSc; Christian Torp-Pedersen, MD, DMSc

From the Department of Cardiology, Gentofte University Hospital, Hellerup (T.K.S., G.H.G., S.Z.A., M.L.H., F.F., P.B., C.T.-P.); National Institute of Public Health, Copenhagen (T.K.S., G.H.G., S.R., J.N.R., S.Z.A.); Department of Cardiology, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen (L.K.); Department of Public Health, University of Copenhagen, Copenhagen (M.M.); and Steno Diabetes Center, Gentofte (A.V.), Denmark.

Correspondence to Dr Tina Ken Schramm, MD, Research Fellow, Department of Cardiology, Gentofte University Hospital, Niels Andersens Vej 65, DK-2900, Hellerup, Denmark. E-mail tks{at}heart.dk

Received June 12, 2007; accepted January 22, 2008.

Background— Previous studies reveal major differences in the estimated cardiovascular risk in diabetes mellitus, including uncertainty about the risk in young patients. Therefore, large studies of well-defined populations are needed.

Methods and Results— All residents in Denmark ≥30 years of age were followed up for 5 years (1997 to 2002) by individual-level linkage of nationwide registers. Diabetes patients receiving glucose-lowering medications and nondiabetics with and without a prior myocardial infarction were compared. At baseline, 71 801 (2.2%) had diabetes mellitus and 79 575 (2.4%) had a prior myocardial infarction. Regardless of age, age-adjusted Cox proportional-hazard ratios for cardiovascular death were 2.42 (95% confidence interval [CI], 2.35 to 2.49) in men with diabetes mellitus without a prior myocardial infarction and 2.44 (95% CI, 2.39 to 2.49) in nondiabetic men with a prior myocardial infarction (P=0.60), with nondiabetics without a prior myocardial infarction as the reference. Results for women were 2.45 (95% CI, 2.38 to 2.51) and 2.62 (95% CI, 2.55 to 2.69) (P=0.001), respectively. For the composite of myocardial infarction, stroke, and cardiovascular death, the hazard ratios in men with diabetes only were 2.32 (95% CI, 2.27 to 2.38) and 2.48 (95% CI, 2.43 to 2.54) in those with a prior myocardial infarction only (P=0.001). Results for women were 2.48 (95% CI, 2.43 to 2.54) and 2.71 (95% CI, 2.65 to 2.78) (P=0.001), respectively. Risks were similar for both diabetes types. Analyses with adjustments for comorbidity, socioeconomic status, and prophylactic medical treatment showed similar results, and propensity score–based matched-pair analyses supported these findings.

Conclusions— Patients requiring glucose-lowering therapy who were ≥30 years of age exhibited a cardiovascular risk comparable to nondiabetics with a prior myocardial infarction, regardless of sex and diabetes type. Therefore, requirement for glucose-lowering therapy should prompt intensive prophylactic treatment for cardiovascular diseases.


 

CLINICAL PERSPECTIVE


Find additional patient-related information at:

Read a summary of this article at americanheart.org

Related Article:

Clinical Summaries
Circulation 2008 117: 1909. [Extract] [Full Text]



This article has been cited by other articles:


Home page
Circ. Res.Home page
T. O. Stolen, M. A. Hoydal, O. J. Kemi, D. Catalucci, M. Ceci, E. Aasum, T. Larsen, N. Rolim, G. Condorelli, G. L. Smith, et al.
Interval Training Normalizes Cardiomyocyte Function, Diastolic Ca2+ Control, and SR Ca2+ Release Synchronicity in a Mouse Model of Diabetic Cardiomyopathy
Circ. Res., September 11, 2009; 105(6): 527 - 536.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
M. Bartnik and F. Cosentino
Dysglycaemia, cardiovascular outcome and treatment. Is the jury still out?
Eur. Heart J., June 1, 2009; 30(11): 1301 - 1304.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
H.-H. Parving, B. M. Brenner, John. J. V. McMurray, D. de Zeeuw, S. M. Haffner, S. D. Solomon, N. Chaturvedi, M. Ghadanfar, N. Weissbach, Z. Xiang, et al.
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design
Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1663 - 1671.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. Sanz, P. R. Moreno, and V. Fuster
The Year in Atherothrombosis
J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1326 - 1337.
[Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
E. Mahmud, J. A. Ormiston, M. A. Turco, J. J. Popma, N. J. Weissman, C. D. O'Shaughnessy, T. Mann, J. J. Hall, T. F. McGarry, L. A. Cannon, et al.
TAXUS Liberte Attenuates the Risk of Restenosis in Patients With Medically Treated Diabetes Mellitus: Results From the TAXUS ATLAS Program
J. Am. Coll. Cardiol. Intv., March 1, 2009; 2(3): 240 - 252.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. W. Worm, S. De Wit, R. Weber, C. A. Sabin, P. Reiss, W. El-Sadr, A. D. Monforte, O. Kirk, E. Fontas, F. Dabis, et al.
Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected With Human Immunodeficiency Virus: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study)
Circulation, February 17, 2009; 119(6): 805 - 811.
[Abstract] [Full Text] [PDF]


Home page
Diabetes Spectr.Home page
E. Roelker
Screening for Coronary Artery Disease in Patients With Diabetes
Diabetes Spectr, July 1, 2008; 21(3): 166 - 171.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. B. Goldfine and J. A. Beckman
Life and Death in Denmark: Lessons About Diabetes and Coronary Heart Disease
Circulation, April 15, 2008; 117(15): 1914 - 1917.
[Full Text] [PDF]